Genexine Inc., of Seoul, South Korea, and Handok Inc., also of Seoul, presented interim results from the phase II trials of long-acting human growth hormone candidate GX-H9 in pediatric growth hormone deficiency and adult growth hormone deficiency (GHD) at the ENDO 2017 meeting in Orlando, Fla. In the pediatric study, GX-H9 demonstrated annualized height velocities comparable to that of active comparator, daily recombinant human growth hormone (hGH) at three months, with data showing mean annualized height velocities of 10.7 cm and 15.3 cm for the two weekly doses of 0.8 mg/kg and 1.2 mg/kg, respectively.